Abstract
Deficiency of carnitine palmitoyltransferase 1A (CPT1A) results in impaired hepatic long-chain fatty acid oxidation and ketogenesis. We have previously described a patient with a severe CPT1A phenotype who is homozygous for the nonsense mutation 478 C > T (R160X). It has been known for some time that gentamicin can promote readthrough of nonsense codons. Recently, a new compound (PTC124) with less clinical toxicity than gentamicin has been indicated as a therapy for patients with nonsense mutations for multiple genetic diseases. The study is designed to investigate whether PTC124 can promote readthrough of the R160X CPT1A mutation and increase normal sized CPT1 protein expression and activity in the patient’s skin fibroblasts. Our study demonstrated that after both PTC 124 and gentamicin treatment, there was an increase in CPT1 activity in patient fibroblasts to levels that are similar to that of the mild Inuit P479L variant. Our results provide additional evidence for proof of principle that PTC124 is a potential therapeutic agent for treating patients with any genetic condition that results from a nonsense mutation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- CPT:
-
carnitine palmitoyltransferase
- PTC:
-
Premature termination codon
- PTC124:
-
(Ataluren) (3-(5-fluorophenyl)-1 2, 4-oxadiazol-3-yl) benzoic acid
References
Bennett MJ, Boriack RL, Narayan S, Lane Rutledge S, Raff ML (2004) Novel mutations in CPT1A define molecular heterogeneity of hepatic carnitine palmitoyltransferase I deficiency. Mol Genet Metab 82:59–63
Bennett MJ, Narayan SB, Santani AB: Carnitine Palmitoyltransferase 1A Deficiency (Sept 2010) in: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, 1997-2010. Available at http://www.genetests.org.
Brown NF, Mullur RS, Subramanian I et al (2001) Molecular characterization of L-CPT I deficiency in six patients: insights into function of the native enzyme. J Lipid Res 42:1134–1142
Buck NE, Wood L, Hu R, Peters HL (2009) Stop codon read-through of a methylmalonic aciduria mutation. Mol Genet Metab 97:244–249
Du M, Wu XL, Welch EM, Hlrawat S, Palta SW, Bedwell DM (2008) PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 105:2064–2069
Esser V, Brown NF, Cowan AT, Foster DW, McGarry JD (1996) Expression of a cDNA isolated from rat brown adipose tissue and heart identifies the product as the muscle isoform of carnitine palmitoyltransferase I (M-CPT-1). J Biol Chem 271:6972–6977
Finkel RS (2010) Read-through strategies for suppression of nonsense mutations in Duchenne/Becker Muscular Dystrophy: aminoglycosides and ataluten(PTC124). J Child Neurol 25(9):1158–1164
Forge A, Schacht J (2000) Aminoglycoside antibiotics. Audiol Neurootol 5:2–22
Greenberg CR, Dilling LA, Thompson GR et al (2009) The paradox of the carnitine palmitoyltransferase type Ia P479L variant in Canadian Aboriginal populations. Mol Genet Metab 96:201–207
Kerem E, Hirawat S, Armoni S et al (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutation: a prospective phase II trail. Lancet 237:719–727
Nagai J, Takano M (2004) Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet 19:159–170
Rajakumar C, Ban MR, Cao H, Yong TK, Bjerregaard P, Hegele RA (2009) Carnitine palmitoyltransferase IA polymorphism P479L is common in Greenland Inuit and is associated with elevated plasma apolipoprotein A-I. J Lipid Res 50:1223–8
Schmitz A, Famulok M (2007) Chemical Biology: Ignore the nonsense. Nature 447:42–43
Strauss AW, Andresen BS, Bennett MJ (2009) Mitochondrial fatty acid oxidation defects. In: Sarafoglou K, Hoffmann GF, Roth KS (eds) Pediatric endocrinology and metabolism. McGraw-Hill, New York, pp 51–70
Welch EM, Barton ER, Zhuo J et al (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87–91
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by: Ronald J.A. Wanders
Competing interest: None declared.
Rights and permissions
About this article
Cite this article
Tan, L., Narayan, S.B., Chen, J. et al. PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation. J Inherit Metab Dis 34, 443–447 (2011). https://doi.org/10.1007/s10545-010-9265-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-010-9265-5